Hypoxic Preconditioned Mesenchymal Stromal Cell Therapy in a Rat Model of Renal Ischemia-reperfusion Injury: Development of Optimal Protocol to Potentiate Therapeutic Efficacy

Myoung Jin Jang1,2, Dalsan You2, Jin Young Park3, Kyung Kim3, Joomin Aum2, Chunwoo Lee4, Geehyun Song5, Ha Chul Shin6, Nayoung Suh7, Yong Man Kim6, Choung-Soo Kim2

1Asan Institute for Life Sciences, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea, 2Department of Urology, Asan Medical Institute of Convergence Science and Technology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea, 3Department of Urology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea, 4Department of Urology, Gyeongsang National University Changwon Hospital, Gyeongsang National University School of Medicine, Changwon, Korea, 5Department of Urology, Kangwon National University Hospital, Chuncheon, Korea, 6Pharmicell Co. Ltd., Seongnam, Korea, 7Department of Pharmaceutical Engineering, College of Medical Sciences, Soon Chun Hyang University, Asan, Korea

Although previous and ongoing clinical studies have used stromal cells during renal ischemia-reperfusion injury (IRI), there is little consensus regarding the optimal protocol. We aimed to optimize the protocol for hypoxic preconditioned human bone marrow-derived mesenchymal stromal cell (HP-hBMSC) therapy in a rat model of renal IRI. We determined the optimal injection route (renal arterial, renal parenchymal, and tail venous injection), dose (low-dose: 1×10^6, moderate-dose: 2×10^6, and high-dose: 4×10^6), and injection period (pre-, concurrent-, and post-IRI). During optimal injection route study, renal arterial injections significantly reduced the decreasing glomerular filtration rate (GFR), as compared to GFRs for the IRI control group, 2 and 4 days after IRI. Therapeutic effects and histological recoveries were the greatest in the group receiving renal arterial injections. During the dose finding study, high-dose injections significantly reduced the decreasing GFR, as compared to GFRs for the IRI control group, 3 days after IRI. Therapeutic effects and histological recoveries were the greatest in the high-dose injection group. While determining the optimal injection timing study, concurrent-IRI injection reduced elevated serum creatinine levels, as compared to those of the IRI control group, 1 day after IRI. Pre-IRI injection significantly reduced the decreasing GFR, as compared with GFRs for the IRI control group, 3 days after IRI. Therapeutic effects and histological recoveries were the greatest in the high-dose injection group. While determining the optimal injection timing study, concurrent-IRI injection reduced elevated serum creatinine levels, as compared to those of the IRI control group, 1 day after IRI. Pre-IRI injection significantly reduced the decreasing GFR, as compared with GFRs for the IRI control group, 1 day after IRI. Therapeutic effects and histological recoveries were the greatest in the concurrent-IRI group. In conclusion, the concurrent-IRI administration of a high dose of HP-hBMSC via the renal artery leads to an optimal recovery of renal function after renal IRI.

Keywords: Ischemia-reperfusion injury, Acute kidney injury, Hypoxia preconditioning, Cell therapy, Renal function

Introduction

Ischemia-reperfusion injury (IRI) is a common early event in a kidney transplant, following a partial nephrectomy. Acute tubular necrosis, impaired kidney function, and organ leukocyte infiltration are some of the major findings for this condition (1). The therapeutic application of stem cells enables the replacement of damaged cells with differentiated stem cells, and allows the use of paracrine mechanisms so that administered stem cells can
exhibit organ-protective actions (2-5). Several studies have demonstrated the effective results of stem cell therapy for achieving recovery from acute kidney injury (AKI) (1, 6-10).

AKI is characterized by a deterioration in renal function over a period of hours to days, causing the kidney to fail to excrete nitrogenous waste products and maintain fluid and electrolyte homeostasis. AKI can result from decreased renal perfusion without cellular injury; an ischemic, toxic, or obstructive insult to the renal tubule; a tubulointerstitial process with inflammation and edema; or a primary reduction in the filtration capacity of the glomerulus (11). In hospitals, IRI is a common etiology of AKI (11, 12). AKI is considered an important independent risk factor for mortality (13). Decades of research have suggested that numerous chemical and biological agents cause beneficial effects in AKI models (14). Promising results have recently been obtained using cell-based therapies for the treatment of AKI and chronic kidney disease (CKD) (15, 16). We also found that a renal arterial infusion of adipose-tissue-derived stromal vascular fraction rescues renal function in a rat model of AKI induced by IRI (17). In a meta-analysis to assess the effects of mesenchymal stromal cell (MSC) therapy in rodent models with AKI or CKD, it was found that MSC therapy tended to be more beneficial in rats with AKI induced by IRI (6). Mechanisms involving angiogenesis, stem cell homing, anti-inflammatory reactions, anti-oxidative stress, and immunomodulation have been established in previous studies (1, 7-10, 18-22). These cells home to the injury sites and function by secreting paracrine factors to limit injury in renal tubules and/or facilitate kidney repair, instead of differentiating into renal tubular cells (14). However, stem cells alone have limited therapeutic efficacies and studies using hypoxic preconditioned human bone marrow-derived mesenchymal stromal cell (HP-hBMSC), which increase stem cell efficacy, are underway (23, 24).

The microenvironment of MSCs in the bone marrow is thought to be immersed in low oxygen tension (hypoxia) (25). It is thus hypothesized that hypoxia can better preserve the biological behavior of MSC from bone marrow. In-vitro culture under hypoxic conditions has been shown to improve proliferation, multilineage differentiation, and colony-forming efficiency (26, 27). In addition, hypoxic preconditioned MSCs (HP-MSC) enhanced survival and promoted retention in vivo and Small MSCs primed with Hypoxia and Calcium ions (SHC-MSCs) exhibit enhanced stemness and immunomodulatory functions (28, 29). Therefore, we evaluated the preclinical efficacy of HP-hBMSCs in a rat model of AKI induced by IRI, to ensure that there was enough evidence for a clinical trial entry.

However, there is little consensus regarding the protocol for optimizing stem cell-based therapies, especially for renal IRI. In our present study, we aimed to develop a protocol for optimizing HP-hBMSC therapy in a rat model of renal IRI. Our analysis consisted of three parts, an optimal injection route study, a dose finding study, and an optimal injection timing study.

Materials and Methods

Isolation and culture of HP-hBMSCs

The study protocol was approved by the Institutional Review Board of Asan Medical Center, Seoul, Republic of Korea (2015–1123), and was in accordance with the declaration of Helsinki. After receiving their informed consent, bone marrow was obtained from healthy donors. All the manufacturing and product testing procedures for hBMSC generation were performed using good manufacturing practices (Pharmicell Co. Ltd., Seongnam, Gyeonggi, Republic of Korea). A previously described isolation protocol was used (30). Cells were cultured in Dulbecco’s modified Eagle’s medium-low glucose (Gibco, Grand Island, NY, US), containing 10% human plate lysate (PLUSTM Cell Culture Supplement, Compass Biomedical, Inc. MA, US). Then, cells at passage 8 were cultured for 72 h in a hypoxia-conditioned incubator (at 37°C in 1% O2, 5% CO2 and 94% N2, for 72 h). After hypoxic preconditioning, the HP-hBMSCs to be injected were harvested using trypsin, washed twice with PBS and once with Plasma Solution A inj. (Multiple Electrolytes Injection, Type I, UPS; CJ Health Care) and resuspended to a final concentration of 1×10^6 cells in Plasma Solution A inj. Criteria for release of HP-hBMSCs for preclinical use included the absence of microbial contamination (bacteria, fungus, mycoplasma, or endotoxin), a viability greater than 70% after assessment using a trypan blue exclusion assay, the proven expression of CD73 and CD105 surface molecules, and absence of CD14, CD34, and CD45, via immune phenotyping by flow cytometric analysis.

Animal care

All aspects of animal care and treatment and the surgical procedures used conformed to the eighth edition of the Guide for the Care and Use of Laboratory Animals, published in 2011. The protocols for performing animal experiments were approved by the Institutional Animal Care and Use Committee of Asan Medical Center (2016-12-
Optimal injection route study

Sixty 13-week-old rats were randomly and equally distributed into the following six groups (10 animals per group): sham, nephrectomy control, IRI control, renal arterial injection, renal parenchymal injection, and tail venous injection groups. Each rat was intramuscularly anesthetized with 0.3 ml of tiletamine (Zoletil; Virbac Laboratories, Carros, France) and xylazine hydrochloride (Rompun, Bayer, Germany) in a 4:1 mixture. Laparotomy was performed in the sham group and right nephrectomy was performed in the nephrectomy control group, while right nephrectomy was performed and IRI of the left kidney was induced in the other four groups. IRI induction was performed in the left kidney as described previously (17). Rats from the renal arterial injection group were injected immediately prior to the induction of renal IRI with 1×10^6 HP-hBMSC/50 μl via a 33-gauge Hamilton syringe (Hamilton, Zurich, Swiss) that was inserted into the distal aorta after clamping the aorta above and below the left renal artery. The injection site was closed using TachoSil® Sealant matrix (BBF Sterilisatoin Service GmbH, Kernen, Germany), and the clamps were removed to restore aortic and renal blood flow. Rats from the renal parenchymal injection group were injected using a Hamilton syringe needle, which was pierced from the lower pole to the upper pole of the kidney. While pulling out the needle, the cells were gradually released from the syringe. Rats from the tail venous injection group were injected with 1×10^6 HP-hBMSC/50 μl through the tail vein using a 26-gauge Kovax-syringe (Koreavaccine, Gyeonggi, Republic of Korea). The renal function of all the rats was evaluated 1 and 4 days before IRI, that followed in the above two studies, and all rats underwent kidney function evaluation 1 and 4 days before IRI, and 1, 3, 4, 7, and 14 days after IRI.

Optimal injection timing study

Sixty 13-week-old rats were randomly and equally distributed into the following six groups (10 animals per group): sham, nephrectomy control, and IRI control, pre-IRI (2 days before IRI), concurrent-IRI, and post-IRI (2 days after IRI) groups. An effective dose of HP-hBMSC was injected through the certain route to protect the renal function in studies to determine the optimal injection route and dose. The IRI induction process was similar to that followed in the above two studies, and all rats underwent kidney function evaluation 1 and 4 days before IRI, and 1, 3, 4, 7, and 14 days after IRI.

Measurement of renal function and tissue preparation

Serum levels of creatinine and blood urea nitrogen (BUN) and urine levels of creatinine were measured at these time points in all animals. Urine was collected from animals in a metabolic cage at 24 h, to estimate the daily urine volume. The glomerular filtration rate (GFR) was calculated using the following equation for the creatinine clearance rate (Ccr): Ccr (ml/min/100 g)=(urine creatinine×24 h urine volume×100)/(serum creatinine×1440×body weight). Quantification of BUN and creatinine levels was performed using standard laboratory equipment at our hospital.

After rats were sacrificed, the kidney tissues of each rat were collected. Half of each kidney was cryopreserved in liquid nitrogen for protein extraction or immunofluorescence staining. The remaining half was fixed in 4% paraformaldehyde and embedded in paraffin prior to sectioning and immunohistochemistry analysis.

Hematoxylin and Eosin staining and histopathological scoring of kidney tissue

Four μm kidney specimen sections were prepared and stained with hematoxylin and eosin for light microscopic analysis. Histopathological scoring was carried out based on a previous study in a blind fashion (31). The tubular injury scores estimated by deriving the percentage of destroyed tubules in the outer medulla that showed a loss of brush border, tubular necrosis, tubular dilatation, and cast formation in 10 randomly chosen, non-overlapping fields (200×) were as follows: 0 (normal histology), 1 (≤ 24%), 2 (25~49%), 3 (50~74%) and 4 (75~100%). Histo-
pathological scoring was described in a previous study (18).

**Sirius red staining**

The slides were dipped in Xylene I and Xylene II, treated with Xylene III, and dipped in ethanol solutions in the following order: 100% to 90% and 80% to 70%. After dipping slides in distilled water thrice, we dipped them in the Harris hematoxylin solution (Sigma, St. Louis cat no: HHS-16, MO, US). Sirius red reagent (Abcam, Cambridge, MA, US) was dropped on the slides and they were incubated. After dipping slides twice in the acid solution, we washed the slides thrice using distilled water, and then dipped them again in ethanol solutions 70% to 80%, 90%, and 100% in 3 steps for each solution. We repeatedly dipped the slides in Xylene I and Xylene II, treated them with Xylene III, and covered the slides with coverslips using permanent mounting media.

**TUNEL Assay**

A TUNEL assay kit (Roche Molecular Biochemicals, Mannheim, Germany) was used. Each sectioned specimen was deparaffinized in xylene I, II, and III, and rehydrated in increasingly diluted ethanol solutions (diluted 100%, followed by 90%, and so on up to 70%). After washing in distilled water, the slides were placed into a pretreatment solution (heat-induced epitope retrieval solution/target retrieval solution). After washing, the protein blocking serum-free ready-to-use (Dako, Glostrup, Denmark) reagent containing 20% FBS was added into the sections, and they were incubated in a humid chamber. The tunnel reaction mixture was dispensed onto the slides, which were incubated in a 37°C humid chamber. Converter-PODs (Converter-Peroxidase) were dispensed and slides were incubated in a 37°C humid chamber. After washing, DAB-starting working solution was added to the specimens and they were incubated.

**Immunohistochemistry**

Kidney sections (4 μm thick) were prepared for immunohistochemistry analysis from rats of each group. Tissue sections were placed on microslides and deparaffinized in xylene, hydrated in increasingly diluted serial ethanol solutions, and immersed in 3% H2O2 to quench endogenous peroxidase activity. To permit antigen retrieval, all sections were microwaved for 15 min in Tris-EDTA buffer (pH 9.0), prepared in distilled water. Next, the sections were incubated for 2 h at an ambient temperature with anti-Ki67 (1:200, Abcam, Cambridge, MA, US), anti-Glutathione reductase (GR; 1:2000, Abcam), and anti-Glutathione peroxidase (GPx; 1:2000, Abcam) antibodies. After washing, the slides were incubated using a biotin-free polymeric horseradish peroxidase-linker antibody conjugate system (Dako, Glostrup, Denmark) for 30 min at an ambient temperature. The slides were washed, and chromogen development was performed for 10 min. The slides were counterstained with Meyer’s hematoxylin and mounted using Immuno-mount (Fisher Scientific, Geel, Belgium). For image analysis, four randomly selected kidney fields per animal in both the cortex and the medulla (40 kidney fields per group) were photographed. Images were recorded at 40× magnification via a Panoramic viewer program software (3D Histechn, Budapest, Hungary). All images were analyzed by using Adobe Photoshop CS2 to quantify signals. The results of proliferation are presented as the percentage of Ki67-positive areas to the total area in each field (cortex and medulla). A semiquantitative analysis was used to express GR and GPx as the percentage of the positive area in a blind fashion.

**Statistical Analysis**

All results are expressed as means±standard error values. Multiple groups were compared using 1-way analysis of variance followed by the Tukey’s HSD (honest significant difference) test for post hoc comparison. All statistical tests were 2-sided, and statistical significance was defined as p<0.05, p<0.01, or p<0.001. p≥0.05 was not considered significant. The data were analyzed by using IBM SPSS Statistics Version 21 (IBM Corporation, Armonk, NY, US).

**Results**

**Viability and characterization of HP-hBMSCs**

The viability of HP-hBMSCs as assessed by trypan blue exclusion assay, was 89.30±7.41%. Flow cytometric analysis showed that HP-hBMSCs were positive for MSC markers CD105 (99.41%), CD73 (99.96%), and HLA-ABC (99.65%), and negative for hematopoietic markers CD45 (0.36%), CD14 (1.42%), CD80 (0.52%), CD86 (0.47%), CD40 (0.23%), and HLA-DR (0.64%) (Fig. 1A). The multilineage differentiation capacity was confirmed after observing the adipogenic and osteogenic differentiation (Fig. 1B).

**Optimal injection route study**

There were no significant differences in body weight and food intake among the groups (Supplementary Fig. S1A, S1B). The weight of the kidneys increased about...
0.6±0.3 g, as compared to the sham group after nephrectomy, but no significant difference was observed between nephrectomy groups (Supplementary Fig. S1C). No gross differences in kidney cross-sections were observed (Supplementary Fig. S1D).

Two and 1 cases of mortality were observed in the renal parenchymal and tail venous injection groups, respectively. Renal arterial injection significantly reduced the extent of elevation in serum BUN values, as compared with those for the IRI control group, 1 and 14 days after IRI (Fig. 2A). Renal arterial injection significantly reduced the extent of elevation in serum creatinine, as compared with the IRI control group, 1, 7, and 14 days after IRI (Fig. 2B). Renal arterial injection significantly reduced the extent of decrease in the GFR, as compared with the IRI control group, 2 and 4 days after IRI (Fig. 2C).

Histopathology scores were significantly different from those for the sham, nephrectomy control, and IRI control groups, but there was no significant difference in values for the IRI control and HP-hBMSC injection groups (Fig. 2D, 2E). Sirius red staining for collagen ratio was significantly increased in the IRI control group, as compared to the sham group. Sirius red staining in the cortex and medulla indicated that the renal arterial and parenchymal injection groups were significantly less fibrotic than the IRI control group (Fig. 2F, 2G). The TUNEL assay showed that apoptosis was more significantly decreased in the renal arterial injection group than in the IRI control group in both the cortex and medulla (Supplementary Fig. S2A, S2B). We used the Ki67 marker to determine proliferation; it was observed that the renal arterial injection group underwent increased proliferation in the cortex and medulla, as compared to the IRI control.
group (Supplementary Fig. S2C, S2D). A greater increase in GR and GPx was observed in HP-hBMSC injection groups, especially for the arterial injection group in comparison with the IRI control group, regardless of the cortex or medulla regions (Supplementary Fig. S2F, S2G).

Dose finding study

There were no significant differences in body weight and food intake among groups (Supplementary Fig. S3A, S3B). The weight of the kidneys increased about 0.5±0.4 g after nephrectomy, as compared to the sham group, but no significant difference was observed between nephrectomy groups (Supplementary Fig. S3C). No gross differences in kidney cross-sections were observed (Supplementary Fig. S3D).

One case of mortality was observed in the IRI control group. High-dose (4×10^6) injection significantly reduced the extent of elevation in serum BUN level, as compared to that for the IRI control group, 1 and 2 days after IRI (Fig. 3A). High-dose injection significantly reduced the extent of elevation in serum creatinine, as compared to the IRI control group, 1 day after IRI (Fig. 3B). High-dose injection significantly reduced the extent of decrease in the GFR, as compared to the IRI control group, 3 days after IRI (Fig. 3C).

Histopathology scores were significantly different from those for the sham, nephrectomy control, and IRI control groups, but there was no significant difference between those for the IRI control and HP-hBMSC injection (Fig. 3D, 3E) groups. Results of Sirius red staining in the cortex and medulla indicated that all HP-hBMSC injection groups were significantly less fibrotic than the IRI control group (Fig. 3F, 3G). The TUNEL assay showed that apoptosis was more significantly decreased in all HP-hBMSC injection groups than in the IRI control group in both the cortex and medulla (Supplementary Fig. S4A, S4B). Ki67 showed that moderate-dose and high-dose injection groups underwent significantly increased proliferation, as compared to the IRI control group in both the cortex and medulla (Supplementary Fig. S4C, S4D). A greater increase
in GR and GPx was observed in moderate-dose and high-dose injection groups, as compared to the IRI control groups, regardless of whether the cortex or medulla was analyzed (Supplementary Fig. S4F, S4G).

Optimal injection timing study

There were no significant differences in body weight and food intake among groups (Supplementary Fig. S5A, S5B). The weight of the kidneys increased about 0.4±0.4 g after nephrectomy, as compared to that of the sham group, but no significant difference was observed between nephrectomy groups (Supplementary Fig. S5C). No gross differences in kidney cross-sections were observed (Supplementary Fig. S5D).

One case of mortality was observed in the IRI control group. Pre-IRI injection significantly reduced the extent of elevation in serum BUN levels, as compared with those of the IRI control group, 1 day (p=0.054) after IRI (Fig. 4A). Pre-IRI injection significantly reduced the extent of decrease in GFRs, as compared with GFRs for the IRI control group, 1 day after IRI (Fig. 4C).

Histopathology scores were significantly different from those for the sham, nephrectomy control, and IRI control groups, but there was no significant difference in values for IRI control and HP-hBMSC injection groups (Fig. 4D and 4E). Sirius red staining in the cortex and medulla indicated that all HP-hBMSC injection groups were significantly less fibrotic than the IRI control group (Fig. 4F and 4G). The TUNEL assay showed that the apoptosis was more significantly decreased in all HP-hBMSC injection groups than in the medulla of the IRI control group (Supplementary Fig. S6A, S6B). Ki67 showed that all HP-hBMSC injection groups underwent significantly increased proliferation, as compared to the IRI control group in both the cortex and medulla (Supplementary Fig. S6C and S6D). A greater increase in GR and GPx levels was observed in all HP-hBMSC injection groups, as com-
Fig. 4. Serum BUN, serum creatinine, GFRs, histopathology scoring, and Sirius red staining of kidney tissue in optimal injection timing study. Serial changes in levels of (A) serum BUN levels, (B) serum creatinine levels, and (C) GFRs. (D) H&E staining for histopathological scoring of each group in the kidney cortex and (E) medulla. Scale bar: 50 μm. (F) Sirius red staining for determining the degree of fibrosis of each group in the kidney cortex and (G) medulla. Scale bar: 100 μm. NS, p > 0.05; *, p < 0.05; **, p < 0.01; ***, and p < 0.001. as compared with the IRI control group.

pared with those in the IRI control group, regardless of the analysis of the cortex or medulla (Supplementary Fig. S6F, S6G).

Discussion

Though several preclinical studies have confirmed the efficacy of stem cell-based therapies for AKI, there is little consensus regarding the optimal protocol for this treatment. Several issues from previous AKI studies remain unresolved. First, the optimal delivery route for cell-based therapies is unknown. Only a few studies had found that arterial delivery via the renal artery most effectively preserved renal function (6, 17, 32). Second, the optimal stem cell dose is unknown. The number of cells transplanted in previous studies varied widely from $5 \times 10^4$ to $1 \times 10^7$ (32, 33). The third and final unresolved issue pertains to the best time to inject cells. However, no study has addressed this question in a rat model of IRI to date. These unresolved issues motivated our current investigation, in which we developed a protocol for optimizing HP-hBMSC therapy in a rat model of IRI.

We have investigated the therapeutic effects of HP-hBMSC in AKI induced by IRI rescue in a rat model. First, an optimal injection route study was conducted, in which different routes of delivery were tested to establish the optimal route. The present study compared the renal arterial, renal parenchymal and tail venous routes for injecting HP-hBMSC. Our findings indicate that the renal arterial injection of HP-hBMSC effectively rescues renal function after AKI is induced by IRI. A meta-analysis of stem cell therapy in kidney diseases found that arterial delivery induced a greater reduction in serum creatinine levels than intravenous or intra-renal arterial injection (6). Our previous study demonstrated that renal arterial injection is more effective than renal parenchymal and tail venous injection for treating AKI (17).

Second, a dose finding study was conducted, in which different doses of HP-hBMSC were tested to establish the optimal dose. We found that a high-dose HP-hBMSC


(4×10^6 HP-hBMSC per injection) treatment resulted in better outcomes; therefore, we subsequently used a high dose. However, Cai et al. (32) reported that maximal therapeutic efficiency was achieved with a renal arterial injection of 1×10^5 MSCs, which was significantly better than that for the group injected with 1×10^6 MSCs. Although it has been reported that the direct local arterial administration of stem cells increased the risk of tissue injury associated with occlusion and embolization, MSCs target oxidative stress and inflammation in both IRI phases, to protect the kidney (34), engraft in the injured tissue, and release soluble factors and microvesicles that promote cell survival and tissue repair (35). Unlike other studies, the effect of adding many cells was better, because cells were injected into the aorta instead of being directly injected into the renal artery. Hence, cells were injected into the syringe immediately prior to injection, to reduce the time for bundles of cells to get accumulated. Thus, it was anticipated that cells spread throughout the entire kidney might have played a role in reducing renal damage. Additionally, in other studies, the direct injection of cells into the renal artery could lead to vasospasms that narrow the vessel tract and make it vulnerable to embolisms, which could aggregate ischemia. The injection of stem cells into the renal artery though the aorta might be more effective than injection via other routes, because the homing of the cells was rapid, and cells were spread throughout the whole kidney.

Third, we aimed to determine the optimal cell injection period. Hence, we examined whether injecting cells at pre-IRI, concurrent-IRI, or post-IRI periods was more effective in protecting renal function. The results confirmed that the functioning and histology of the kidney was most effectively rescued from renal IRI through the pre- and concurrent-IRI injection of HP-hBMSC. There was a difference in the timing of injection of cells, but injecting cells within 24 h, especially 1 h to 12 h after injury, was more effective. Lange et al. reported that transplanting MSCs either immediately or 24 h post-I/R resulted in significant renoprotection (21), and Liu et al. (36) reported that injecting cells immediately after ischemia or 1 h post-IRI yielded higher renoprotective and anti-inflammatory effects than when MSCs were administered 12 or 24 h post-IRI. IRI started an initiation stage, in which endothelial dysfunction progressed for several hours after injury, and progressed from the extension stage to the maintenance stage over time. Basile and Yoder (37) reported that treatment at the initiation stage resulted in the preservation of function, especially when treatments affecting tone (e.g., supplementation of NO or vasoconstrictor antagonists) were provided, while treatment at the extension stage lacked efficacy. Similarly, treatments that disrupt endothelial leukocyte interactions were effective when provided during initiation. Our current findings in the rat model suggest that that renal arterial injection of HP-hBMSC might be performed clinically when the kidney is exposed during surgery, while simultaneously assessing renal function impairment.

When the residual kidney is damaged by IRI during partial nephrectomy, HP-hBMSC could be injected into the renal artery during surgery for achieving renal function recovery; it would also be possible to perform this procedure for a transplanted kidney. Furthermore, the intra-renal arterial injection of HP-hBMSC could be performed through catheterization, by means of angiography or fluoroscopy for AKI, due to medical conditions. We believe that this would decrease the risk of chronic renal failure. In conclusion, administering a renal arterial, concurrent-IRI injection of high-dose HP-hBMSC can enable the recovery of renal function along with histomorphometric changes in a rat model of IRI.

Acknowledgements
This research was supported by a grant of the Korea Health Technology R&D Project through the Korea Health Industry Development Institute (KHIDI), funded by the Ministry of Health & Welfare, Republic of Korea (grant number: HI15C0925).

We thank the Comparative Pathology Core facility at the ConveRgence mEDicine research cenTer (CREDIT), Asan Medical Center for measure the serum BUN, serum creatinine and urine creatinine.

Potential Conflict of Interest
There are no conflicts of interest to declare.

Supplementary Materials
Supplementary data including three figure can be found with this article online at http://pdf.medrang.co.kr/paper/pdf/IJSC/IJSC-11-s18073.pdf.

References
2. Gnecci M, He H, Liang OD, Melo LG, Morello F, Mu H, Noiseux N, Zhang L, Pratt RE, Ingwall JS, Dzau VJ. Paracrine action accounts for marked protection of ische-
mic heart by Akt-modified mesenchymal stem cells. Nat Med 2005;11:367-368
3. Kinnaird T, Stabile E, Burnett MS, Lee CW, Barr S, Fuchs S, Epstein SE. Marrow-derived stromal cells express genes encoding a broad spectrum of arteriogenic cytokines and promote in vitro and in vivo arteriogenesis through paracrine mechanisms. Circ Res 2004;94:678-685
27. Hoch AI, Leach JK. Concise review: optimizing expansion and differentiation of bone marrow mesenchymal stem/stromal cells for clinical applications. Stem Cells Transl Med 2015;4:412

166 International Journal of Stem Cells 2018;11:157-167


Fig. S1. Body weights and food consumption of rats, and kidney weights and morphology in optimal injection route study. Changes in the (A) Body weight, (B) Food consumption, and (C) Kidney weights of each group during the experiment. (D) Kidney morphology of each group.
**Fig. S2.** Immunohistochemistry of TUNEL, Ki67, GR and GPx in optimal injection route study. (A) TUNEL assay for the detection of apoptotic cells of each group in the kidney cortex and (B) medulla. (C) Ki67 staining for detecting cell proliferation of each group in the kidney cortex and (D) medulla. (E) Glutathione reductase staining for oxidative cell detection in each group of the kidney cortex and (F) medulla. (G) Glutathione peroxidase staining for oxidative detection of each group in the kidney cortex and (H) medulla. Scale bar 100 μm. NS, p > 0.05; *, p < 0.05; **, p < 0.01; ***, and p < 0.001, as compared with the IRI control group.
Fig. S3. Body weights and food consumption in rats, and kidney weights and morphology in the dose finding study. Graphs showing changes in (A) Body weight, (B) Food consumption, and (C) Kidney weight of each group during the experiment. (D) Kidney morphology of each group.
Fig. S4. Immunohistochemistry of TUNEL, Ki67, GR and GPx in dose finding study. (A) TUNEL assay for detecting apoptotic cells in each group of the kidney cortex and (B) medulla. (C) Ki67 staining for detecting cell proliferation in each group in the kidney cortex and (D) medulla. (E) Glutathione reductase staining for detecting oxidative cells in each group in the kidney cortex and (F) medulla. (G) Glutathione peroxidase staining for the oxidative detection of each group in the kidney cortex and (H) medulla. Scale bar: 100 μm. NS, p > 0.05; *, p < 0.05; **, p < 0.01; ***, and p < 0.001, as compared with the IRI control group.
Fig. S5. Body weights and food consumption of rats, and kidney weights and morphology in the optimal injection timing study. Graphs showing the changes in (A) Body weight, (B) Food consumption, and (C) Kidney weight in each group during the experiment. (D) Kidney morphology of each group.
Fig. S6. Immunohistochemistry of TUNEL, Ki67, GR, and GPx in optimal injection timing study. (A) TUNEL assay for the detection of apoptotic cells of each group in the kidney cortex and (B) medulla. (C) Ki67 staining for detecting cell proliferation in each group of the kidney cortex and (D) medulla. (E) Glutathione reductase staining for oxidative cell detection in each group in the kidney cortex and (F) medulla. (G) Glutathione peroxidase staining for oxidative detection of each group in the kidney cortex and (H) medulla. Scale bar: 100 μm. NS, p > 0.05; *, p < 0.05; **, p < 0.01; ***, p < 0.001, as compared with the IRI control group.